I felt the same way. I don’t see immunotherapy as a major competition to K. I’m really hoping they can work together. Although I don’t own any shares in JUNO, I’m sad to see that cancer patients lost one potential treatment option in CAR-T.

Quote:

---

What I say is, the world needs as many different kinds of treatments as possible. Not any one drug is going to work for everyone. I cheer when some drug works against some disease, whether or not a company whose stock I own has a rival drug in development. This is terrible news that JUNO's treatment may be dangerous.

---